ConductScience.org, home

Paper23344265

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

Carpenter RO and 8 others. Clin Cancer Res, 2013. Cited by 564 papers, by iCite.

Cite this record

ConductScience Library. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Papers, record 23344265. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23344265

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
PubMed
Journal
Clin Cancer Res
PubMed
Year
2013
PubMed
Publication types
Journal Article, Research Support, N.I.H., Intramural
PubMed
Citations, by iCite
564
iCite
Relative citation ratio, by iCite
14.5
iCite
Revised in PubMed
2025-05-29
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Carpenter RORobert O
2Evbuomwan MOMoses O
3Pittaluga SStefania
4Rose JJJeremy J
5Raffeld MMark
6Yang SShicheng
7Gress RERonald E
8Hakim FTFrances T
9Kochenderfer JNJames N

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
B-Cell Maturation AntigenMajor topic
Multiple MyelomaMajor topic
Receptors, Antigen, T-CellMajor topic
T-LymphocytesMajor topic
Animals
Cell Line, Tumor
Cytotoxicity, Immunologic
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Immunotherapy, Adoptive
Interleukin Receptor Common gamma Subunit
K562 Cells
Mice
Mice, Inbred NOD
Mice, Knockout
Mice, SCID
Reverse Transcriptase Polymerase Chain Reaction
Xenograft Model Antitumor Assays

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
ZIA BC011439Intramural NIH HHSUnited StatesZIABC011439PubMed and NIHNIH RePORTER
ZIABC010957NIHNIH RePORTER
ZICBC010934NIHNIH RePORTER
ZICBC011029NIHNIH RePORTER
ZICBC011087NIHNIH RePORTER

Download CSV of grants

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02215967Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple MyelomaBackgroundClinicalTrials.gov
NCT03706547Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MMBackgroundClinicalTrials.gov
NCT05849610Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple MyelomaBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in23444214Zoom Zoom: racing CARs for multiple myeloma.https://conductscience.org/library/papers/23444214

Source PubMed

Download CSV of comments and corrections

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120631379Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.Blood2010https://conductscience.org/library/papers/20631379PubMed
221658650Reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma: a concise review.Clin Lymphoma Myeloma Leuk2011https://conductscience.org/library/papers/21658650PubMed
321522124Treatment of multiple myeloma.Nat Rev Clin Oncol2011https://conductscience.org/library/papers/21522124PubMed
416322746Supernatural T cells: genetic modification of T cells for cancer therapy.Nat Rev Immunol2005https://conductscience.org/library/papers/16322746PubMed
516818641Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.Cancer Res2006https://conductscience.org/library/papers/16818641PubMed
61396583A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma.EMBO J1992https://conductscience.org/library/papers/1396583PubMed
711509691An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway.Science2001https://conductscience.org/library/papers/11509691PubMed
8781899Distribution of plasma cells and other cells containing immunoglobulin in the respiratory tract of normal man and class of immunoglobulin contained therein.Thorax1976https://conductscience.org/library/papers/781899PubMed
922127019Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.Mol Ther2012https://conductscience.org/library/papers/22127019PubMed
1021852787Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.Leukemia2012https://conductscience.org/library/papers/21852787PubMed
1122804669Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.Br J Haematol2012https://conductscience.org/library/papers/22804669PubMed
1219561539Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.J Immunother2009https://conductscience.org/library/papers/19561539PubMed
1321830940Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.N Engl J Med2011https://conductscience.org/library/papers/21830940PubMed
1421777223Monoclonal antibodies in the treatment of multiple myeloma.Br J Haematol2011https://conductscience.org/library/papers/21777223PubMed
1521157437T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.Mol Ther2011https://conductscience.org/library/papers/21157437PubMed
1617968879Rheumatoid arthritis fibroblast-like synoviocytes express BCMA and are stimulated by APRIL.Arthritis Rheum2007https://conductscience.org/library/papers/17968879PubMed
1712579196Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.Nat Med2003https://conductscience.org/library/papers/12579196PubMed
1820428207Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.Leukemia2010https://conductscience.org/library/papers/20428207PubMed
1915692072Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.Blood2005https://conductscience.org/library/papers/15692072PubMed
2021849486Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.Blood2011https://conductscience.org/library/papers/21849486PubMed

See all 49 referencesDownload CSV of references

Cited by408

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 564 citations.

PMIDTitleJournalYearIn PapersSource
42980050Bispecific antibodies targeting B-cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions.Cancer2026https://conductscience.org/library/papers/42980050PubMed
42974396Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles.Nanoscale Adv2026https://conductscience.org/library/papers/42974396PubMed
42806527Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.Hematol Oncol2026https://conductscience.org/library/papers/42806527PubMed
42755123BAFF and APRIL Receptors in B Cell Immunity and Autoimmunity.Immunol Rev2026https://conductscience.org/library/papers/42755123PubMed
42733076Enhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers.Nat Commun2026https://conductscience.org/library/papers/42733076PubMed
42708148Radiocopper in BCMA-targeted immunotheranostics of myeloma.Theranostics2026https://conductscience.org/library/papers/42708148PubMed
42686747T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42686747PubMed
42681422Modeling the Application of Chimeric Antigen Receptor T Cell Therapy to Eliminate Alloantibodies in Mice.Methods Mol Biol2026https://conductscience.org/library/papers/42681422PubMed
42605790Metabolic activation using fructose-1,6-bisphosphate microparticles of non-virally LNP-generated CAR-macrophages induces anti-tumor immune responses.J Mater Chem B2026https://conductscience.org/library/papers/42605790PubMed
42405950Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation.J Exp Med2026https://conductscience.org/library/papers/42405950PubMed
42315760Current status and challenges of TCR-T cell therapy for AML/MDS.Int J Hematol2026https://conductscience.org/library/papers/42315760PubMed
42157940Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.Int J Biol Sci2026https://conductscience.org/library/papers/42157940PubMed
42104450Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases.J Hematol Oncol2026https://conductscience.org/library/papers/42104450PubMed
41976339Extracellular Vesicle IL5RA and BCMA in Serum Enable Non-Invasive Risk Stratification of Multiple Myeloma.Cancers (Basel)2026https://conductscience.org/library/papers/41976339PubMed
41942445Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.Nat Commun2026https://conductscience.org/library/papers/41942445PubMed
41892338Empowerment of CAR-T Cells by IL-7 and IL-15 Boosts Their Efficacy Against HER2-Positive Tumors with Enhanced Expansion and Persistence.Cells2026https://conductscience.org/library/papers/41892338PubMed
41871876Limited expression of B-cell maturation antigen in acute myeloid leukemia.J Immunother Cancer2026https://conductscience.org/library/papers/41871876PubMed
41861264Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma.JCO Clin Cancer Inform2026https://conductscience.org/library/papers/41861264PubMed
41749939Soluble B-Cell Maturation Antigen as a Prognostic Marker for Progression-Free Survival in Multiple Myeloma Treated with BCMA-Directed Therapies: A Systematic Review and Meta-Analysis.Cancers (Basel)2026https://conductscience.org/library/papers/41749939PubMed
41749925The Role of Rarely Studied Chemokines in Tumor Progression in Multiple Myeloma (MM).Cancers (Basel)2026https://conductscience.org/library/papers/41749925PubMed

See all 408 cited byDownload CSV of cited by

Genes22

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CARS1833PubTator's text mininghttps://conductscience.org/library/genes/833NCBI Gene
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD247919PubTator's text mininghttps://conductscience.org/library/genes/919NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CD34947PubTator's text mininghttps://conductscience.org/library/genes/947NCBI Gene
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
LAMP13916PubTator's text mininghttps://conductscience.org/library/genes/3916NCBI Gene
MAPK85599PubTator's text mininghttps://conductscience.org/library/genes/5599NCBI Gene
NCAM14684PubTator's text mininghttps://conductscience.org/library/genes/4684NCBI Gene
NGF4803PubTator's text mininghttps://conductscience.org/library/genes/4803NCBI Gene
NGFR4804PubTator's text mininghttps://conductscience.org/library/genes/4804NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene
POTEF728378PubTator's text mininghttps://conductscience.org/library/genes/728378NCBI Gene
SCFV652070PubTator's text mininghttps://conductscience.org/library/genes/652070NCBI Gene
SP680320PubTator's text mininghttps://conductscience.org/library/genes/80320NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

See all 22 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23344265

GET https://conductscience.org/api/papers/v1/23344265/references?page=2